A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction

医学 心力衰竭 射血分数 内科学 地高辛 心脏病学 依瓦布拉定 缬沙坦 心率 血压
作者
Jasper Tromp,Wouter Ouwerkerk,Dirk J. van Veldhuisen,Hans L. Hillege,A. Mark Richards,Peter van der Meer,Inder Anand,Carolyn S.P. Lam,Adriaan A. Voors
出处
期刊:Jacc-Heart Failure [Elsevier]
卷期号:10 (2): 73-84 被引量:111
标识
DOI:10.1016/j.jchf.2021.09.004
摘要

This study sought to estimate and compare the aggregate treatment benefit of pharmacological therapy for heart failure (HF) with reduced ejection fraction.The estimated treatment effects of various combinations of contemporary HF medical therapies are not well characterized.We performed a systematic network meta-analysis, using MEDLINE/EMBASE and the Cochrane Central Register of Controlled Trials for randomized controlled trials published between January 1987 and January 2020. We included angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers (BB), mineralocorticoid receptor antagonists (MRAs), digoxin, hydralazine-isosorbide dinitrate, ivabradine, angiotensin receptor-neprilysin inhibitors (ARNi), sodium glucose cotransporter-2 inhibitors (SGLT2i), vericiguat, and omecamtiv-mecarbil. The primary outcome was all-cause death. We estimated the life-years gained in 2 HF populations (BIOSTAT-CHF [BIOlogy Study to TAilored Treatment in Chronic Heart Failure] and ASIAN-HF [Asian Sudden Cardiac Death in Heart Failure Registry]).We identified 75 relevant trials representing 95,444 participants. A combination of ARNi, BB, MRA, and SGLT2i was most effective in reducing all-cause death (HR: 0.39; 95% CI: 0.31-0.49); followed by ARNi, BB, MRA, and vericiguat (HR: 0.41; 95% CI: 0.32-0.53); and ARNi, BB, and MRA (HR: 0.44; 95% CI: 0.36-0.54). Results were similar for the composite outcome of cardiovascular death or first hospitalization for HF (HR: 0.36; 95% CI: 0.29-0.46 for ARNi, BB, MRA, and SGLT2i; HR: 0.44; 95% CI: 0.35-0.56 for ARNi, BB, MRA, and omecamtiv-mecarbil; and HR: 0.43; 95% CI: 0.34-0.55 for ARNi, BB, MRA, and vericiguat). The estimated additional number of life-years gained for a 70-year-old patient on ARNi, BB, MRA, and SGLT2i was 5.0 years (2.5-7.5 years) compared with no treatment in secondary analyses.In patients with HF with reduced ejection fraction, the estimated aggregate benefit is greatest for a combination of ARNi, BB, MRA, and SGLT2i.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
33完成签到 ,获得积分10
刚刚
刚刚
yufanhui应助小小强采纳,获得10
1秒前
2秒前
脑洞疼应助诚心采白采纳,获得10
2秒前
nkh完成签到,获得积分10
2秒前
学术菜狗180完成签到,获得积分10
3秒前
www发布了新的文献求助10
3秒前
fish发布了新的文献求助30
3秒前
西门放狗发布了新的文献求助100
3秒前
3秒前
4秒前
旺旺发布了新的文献求助10
4秒前
玥来玥好发布了新的文献求助10
5秒前
烟花应助羽化采纳,获得10
6秒前
典雅的荣轩完成签到,获得积分10
7秒前
华仔应助inshialla采纳,获得10
7秒前
guoguo发布了新的文献求助10
7秒前
wst完成签到,获得积分10
8秒前
8秒前
哎嘿发布了新的文献求助10
8秒前
吴彦祖发布了新的文献求助10
10秒前
旅行的小七仔完成签到,获得积分10
10秒前
10秒前
xhw完成签到,获得积分10
11秒前
nini应助dejavu采纳,获得10
11秒前
白水发布了新的文献求助10
11秒前
wst发布了新的文献求助10
11秒前
NexusExplorer应助yaohan1121采纳,获得10
11秒前
11秒前
橙子完成签到,获得积分10
11秒前
Ava应助不安的橘子采纳,获得10
11秒前
12秒前
12秒前
虚心完成签到 ,获得积分10
12秒前
上官若男应助俏皮小伙采纳,获得10
13秒前
大模型应助hay采纳,获得10
14秒前
橙子发布了新的文献求助20
15秒前
15秒前
谭云兮发布了新的文献求助10
16秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
A Dissection Guide & Atlas to the Rabbit 600
中国心血管健康与疾病报告2023(要完整的报告) 500
Ожившие листья и блуждающие цветы. Практическое руководство по содержанию богомолов [Alive leaves and wandering flowers. A practical guide for keeping praying mantises] 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3102188
求助须知:如何正确求助?哪些是违规求助? 2753430
关于积分的说明 7623767
捐赠科研通 2406086
什么是DOI,文献DOI怎么找? 1276587
科研通“疑难数据库(出版商)”最低求助积分说明 616881
版权声明 599103